MapLight Therapeutics, Inc.
MPLT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001770069
In the last 90 days, MapLight Therapeutics, Inc. insiders filed 3 open-market purchases and 8 sales; 105 institutions reported holding it in 13F filings for Q2 2026, worth $941.0M in total; no superinvestor holds it.
Holders of 5% or more of MPLT
Holders whose latest Schedule 13D or 13G filing reports 5% or more of MapLight Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Catalyst4, Inc. | 13D | 45.10%19.7M shares | New | Nov 20, 20251 filing | Nov 20, 2025 | SEC |
| Novo Holdings A/S | 13D | 8.40%3.69M shares | New | Nov 4, 20251 filing | Nov 4, 2025 | SEC |
| T. Rowe Price Investment Management, Inc. | 13G | 6.20%2.80M shares | New | Feb 17, 20261 filing | Feb 17, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
3 Schedule 13D and 13G filings on MapLight Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Feb 17, 202610:28 AM ET | T. Rowe Price Investment Management, Inc. | 13G | 6.20%2.80M shares | New | Dec 31, 2025 | SEC |
| Nov 20, 20257:37 PM ET | Catalyst4, Inc.and 3 others | 13D | 45.10%19.7M shares | New | Oct 28, 2025 | SEC |
| Nov 4, 20254:21 PM ET | Novo Holdings A/S | 13D | 8.40%3.69M shares | New | Oct 28, 2025 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell MapLight Therapeutics, Inc. shares.
No Form 144 notices for MapLight Therapeutics, Inc. are on file.